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CORRESPONDENCE
Letters to the Editor
Endothelial Progenitor Cells
in Coronary Artery Disease
We have been prompted to write by the small study of Güven
et al. (1) showing increased endothelial progenitor cell (EPC)
colonies in patients with coronary artery disease (CAD). In
contrast, a wide literature demonstrates that the extent of the
EPC pool is an indicator of cardiovascular health, as EPCs
negatively correlate with severity of both peripheral and coro-
nary atherosclerosis (2,3).
The investigators attribute their paradoxical results to the longer
culture method they used to distinguish between true EPCs and
circulating angiogenic cells (CACs) in comparison with previous
studies. Even if we consider that earlier studies evaluated CACs
rather than true EPCs, the findings by Güven et al. (1) are
contrasting, because they report higher CACs in patients with
CAD. The researchers hypothesize that significantly ischemic
CAD triggers the mobilization of EPCs/CACs from bone mar-
row. However, patients with actual myocardial ischemia, for whom
increase in EPCs/CACs have been previously demonstrated, were
excluded from the study, and only patients with stable CAD were
enrolled. Moreover, whereas EPC colonies directly correlated with
maximum stenosis, they did not correlate with the number of
diseased vessels, which should be more informative on the extent
of myocardial ischemia.
We suggest that the use of intravascular ultrasound may provide
further information on coronary atherosclerosis and help explain
the paradoxical results when CAD is assessed angiographically.
Finally, should the data by Güven et al. (1) really reflect a
previously unknown regulation of EPCs in CAD, we would like to
offer a counter explanation: the increase in circulating cells with
high angiogenic potential dependent on CAD severity may be
causally related to plaque angiogenesis and growth (4) the Janus
face of EPCs in cardiovascular diseases.
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Reply
We would like to thank Dr. Fadini and colleagues for their
comments regarding our study (1) recently published in JACC. Dr.
Fadini et al. point out that our data, which shows that the numbers
of endothelial progenitor cells (EPCs) and circulating angiogenic
cells (CACs) in the blood of patients referred for cardiac cathe-
terization are increased in those patients with angiographically
significant coronary artery disease (CAD), differs from the results
of some previously published studies. We agree. But as discussed in
our study and highlighted by Drs. Leor and Marber in an
accompanying editorial in JACC (2), it is critical when comparing
different studies that the type of circulating angiogenic cells be
precisely defined. Indeed, a recent study by Yoder et al. (3)
suggested that culture techniques commonly used to quantify
EPCs actually measure myeloid progenitor cells (3). In our study,
we used rigorous histological and flow cytometry techniques to
quantify EPCs and CACs (not simply a longer culture method, as
suggested by Dr. Fadini et al.). Furthermore, whereas we com-
pared these cell numbers to angiographically defined CAD among
patients across a wide spectrum of disease severity, many previous
studies identified atherosclerotic disease or its absence noninva-
sively, which may seriously limit sensitivity and specificity. We
agree that a more precise definition of atherosclerosis by, for
example, use of intravascular ultrasound, may add to our under-
standing of the relationship between the different EPC subsets and
CAD.
From our observations, we speculated that significant myocar-
dial ischemia may be a proximal determinant of EPC number in
the peripheral blood. Dr. Fadini et al. question this, but in support
of their opinion they wrongly state that patients with actual
myocardial ischemia were excluded from our study. Although
patients with acute myocardial infarction and unstable angina were
excluded from our investigation, the majority of our patients with
significant CAD were symptomatic (and anginal symptoms likely
underestimate the frequency of true myocardial ischemia). Impor-
tantly, we observed the highest numbers of circulating EPCs and
CACs in patients selected clinically to require revascularization. Of
relevance, previous studies have shown an increase in circulating
EPCs in patients with unstable angina (4) or acutely in response to
exercise-induced ischemia (5), observations that appear consistent
with the hypothesis that ischemia may be an important factor for
the number of circulating EPCs.
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Adjunctive Thrombectomy in
Acute Myocardial Infarction:
For Some but Not for All
We read with interest the report by Silva-Orrego et al. (1)
regarding the effects of thrombus aspiration on myocardial reper-
fusion in the setting of primary angioplasty. The study reported a
significant enhancement in myocardial reperfusion by a strategy of
manual thrombus aspiration before stenting on top of abciximab
administration. However, in our opinion some concerns exist
about the results of this study. First, the investigators randomized
patients with acute myocardial infarction (MI) to a conventional
stent-assisted primary angioplasty versus a strategy applying man-
ual aspiration device before stent, regardless of angiographic
appearance of thrombus. Early studies evaluating the feasibility of
thrombectomy in the setting of thrombus-containing lesion and
acute MI clearly reported on the efficacy of thrombectomy devices
in reducing thrombus burden at target lesion, consequently limit-
ing distal embolization and no-reflow phenomenon (2,3).
Unfortunately, Silva-Orrego et al. (1) did not provide data
concerning thrombus burden at baseline angiography, nor on
thrombus removal after device use. Thus, the reported reduction in
distal embolization rate may not be univocally ascribed to the
device effect, as other factors may affect this result, such as
differences in thrombus burden of culprit lesions.
Second, the researchers found a rate of postprocedural myocar-
dial blush grade (MBG) 2/3 in both arms, which is surprisingly
higher than expected, based on Thrombolysis In Myocardial
Infarction (TIMI) flow achieved after the intervention, and on
time-to-treatment reported in this cohort. In the largest study
validating the angiographic reperfusion, MBG was strongly af-
fected by epicardial flow, being that patients showing TIMI flow
grade 3 very rarely reached an adequate blush (4). Indeed, it has
been shown that the effectiveness of myocardial reperfusion after
primary angioplasty, as assessed by ST-segment resolution and
MBG is clearly time-dependent (5).
In conclusion, to avoid conflicting results, we believe that future
studies evaluating thrombectomy as adjunctive strategy in the
setting of primary angioplasty should enroll only patients with
angiographically documented thrombus at the lesion site, and that
reperfusion findings should be carefully evaluated according to
time-to-treatment.
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We appreciated the comments by Dr. Napodano and colleagues
and would like to address their concern. The DEAR-MI (De-
thrombosis to Enhance Acute Reperfusion in Myocardial Infarc-
tion) study (1) included consecutive randomization of acute myo-
cardial infarction (AMI) patients fulfilling the inclusion criteria
regardless of angiographic evidence of thrombus based on the
assumption that thrombus is always present in AMI. Compared
with angioscopy, the presence of intracoronary thrombus is signif-
icantly underestimated by angiography (2). In our randomized
population, 73% of controls and 81% of patients undergoing
aspiration showed an occluded vessel with Thrombolysis In Myo-
cardial Infarction (TIMI) flow grade 0/1 at the initial angiogram,
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